Immuneering Corp (IMRX)
1.47
+0.04
(+2.80%)
USD |
NASDAQ |
Apr 26, 16:00
1.47
0.00 (0.00%)
Pre-Market: 20:00
Immuneering Research and Development Expense (Quarterly): 11.91M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 11.91M |
| September 30, 2023 | 10.05M |
| June 30, 2023 | 9.453M |
| March 31, 2023 | 10.21M |
| December 31, 2022 | 9.872M |
| September 30, 2022 | 9.364M |
| June 30, 2022 | 7.981M |
| March 31, 2022 | 9.058M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.950M |
| September 30, 2021 | 6.208M |
| June 30, 2021 | 6.992M |
| March 31, 2021 | 5.391M |
| December 31, 2020 | 4.890M |
| September 30, 2020 | 4.069M |
| June 30, 2020 | 3.221M |
| March 31, 2020 | 2.823M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.823M
Minimum
Mar 2020
11.91M
Maximum
Dec 2023
7.465M
Average
7.966M
Median
Research and Development Expense (Quarterly) Benchmarks
| Geron Corp | 32.91M |
| SELLAS Life Sciences Group Inc | 5.097M |
| Elicio Therapeutics Inc | 6.157M |
| Vistagen Therapeutics Inc | 4.538M |
| ADMA Biologics Inc | 0.4455M |